New research reveals that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Research printed in a major medical journal shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying these drugs need to be informed of the danger of rapid weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass in about 18 months.
Weighing Treatments
The analysis, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of these new drugs with older methods.
The team point out that people who shed pounds through dieting usually experience a less rapid weight regain—around 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Experts suggest the mechanism of the injections is key to understanding the heightened regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means appetite is unsuppressed, making overeating much more probable."
A Chronic Condition?
The NHS recommend the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, due to the likelihood of weight regain, the therapy is often long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the chronic character of obesity," akin to managing conditions like hypertension.
Patient Experiences
Users who have come off the medication report a sudden resurgence of cravings.
"I experienced something flipping and you're instantly starving," described an individual.
The struggle is worsened if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Widespread Use
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is higher among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are effective tools for shedding pounds, they are not a permanent solution and lasting health benefits likely depends on ongoing behavioural support.
